Skip to main content

Table 1 Patient, mammographic and tumor characteristics (primary study sample)

From: Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study

 

Study sample (n = 1403)

1C (n = 394) n (%) or mean

SC (n = 1009) n (%) or mean

p value

Missing data

PATIENT CHARACTERISTICS

Age at diagnosis

60.8

60.2

0.055

0 %

Menopausal at diagnosis

  

0.150

6.4 %

 Yes

297 (81 %)

794 (84 %)

  

 No

71 (19 %)

151 (16 %)

  

BMI

24.8

25.8

<0.001

3.2 %

HRT use at diagnosis

  

<0.001

5.1 %

 No

280 (75 %)

802 (84 %)

  

 Yes

93 (25 %)

156 (16 %)

  

Oral contraceptive use

  

0.145

3.1 %

 No

78 (21 %)

239 (24 %)

  

 Yes

300 (79 %)

742 (76 %)

  

Parity

    

 Nulliparous

61 (15 %)

158 (16 %)

0.997

2.2 %

 Number of births, parous women

2.13

2.14

0.816

0 %

 Age at first birth, parous women

25.7

25.4

0.341

0 %

Family history of breast cancer (first degree)

  

0.029

7.8 %

 No

284 (77 %)

762 (82 %)

  

 Yes

84 (23 %)

162 (18 %)

  

MAMMOGRAPHIC CHARACTERISTICS

Time (months) from measure to diagnosis

15.3 (median)

24.6 (median)

<0.001

 

Mammographic percent density

23.5 (median)

17.6 (median)

<0.001

 

TUMOR CHARACTERISTICS

n (%) or mean

n (%) or mean

  

Tumor size, mm

19.5

15.6

<0.001

7.3 %

Lymph node metastasis

  

<0.001

0.4 %

 No

356 (91 %)

960 (96 %)

  

 Yes

37 (9 %)

45 (4 %)

  

Tumor grade, Elston

  

<0.001

42 %

 1

35 (16 %)

147 (25 %)

  

 2

109 (50 %)

323 (54 %)

  

 3

75 (34 %)

127 (21 %)

  

ER status

  

<0.001

27 %

 Negative

57 (19 %)

72 (10 %)

  

 Positive

239 (81 %)

659 (90 %)

  

PR status

  

0.002

28 %

 Negative

109 (38 %)

201 (28 %)

  

 Positive

181 (62 %)

520 (72 %)

  
  1. p values for difference between the 1C and SC group were calculated by two-sided t test for continuous variables; and by chi square tests for categorical variables. See Additional file 1: Table S1 for patient and mammographic data for the validation sample
  2. 1C interval breast cancer, SC screen-detected breast cancer, BMI body mass index, HRT hormone replacement therapy, ER estrogen receptor, PR progesterone receptor